TECE19-Clinical and Translational Dermatology
Advanced Therapies and Biomedical Technologies / IBS-TECe19 / Consolidated
Multidisciplinary research group made up of clinical and basic researchers aimed at a better knowledge of inflammatory and oncological skin diseases and the clinical translation of some therapeutic advances in the field of advanced therapies.
Research lines
- Immune-mediated inflammatory skin diseases (hidradenitis suppurativa, atopic dermatitis, psoriasis, alopecia areata, urticaria...): aetiopathogenesis and new predictive biomarkers of severity and therapeutic response.
- Analysis of barrier function and skin homeostasis in inflammatory skin diseases and impact of the exposome. Study of predictive parameters of severity and response to treatments. Impact of drugs and emollients on barrier function.
- Development and application of therapeutic advances in cutaneous oncological and immune-mediated inflammatory diseases: advanced therapies (cellular therapy and tissue engineering), biological drugs and biomedical technologies.
- Study of comorbidities in immune-mediated skin inflammatory diseases: description, impact, disease modification and preventive strategies.
- Cutaneous oncology: epidemiology and biomarkers in melanoma and non-melanoma skin cancer.
- Sexually transmitted infections: epidemiological analysis and primary prevention strategies.
- Quality of life in dermatology and primary prevention of skin diseases.
- Image and artificial intelligence: applications in dermatology.
Keywords
Immune-mediated skin diseases. Skin cancer. Cutaneous homeostasis. Quality of life. Dermatology. Cellular therapy. Tissue engineering.
BEATRIZ ESPADAFOR LOPEZ
IRENE NAVARRO NAVARRO
TRINIDAD MONTERO VILCHEZ
MARIA ISABEL QUIÑONES VICO
MANUEL SANCHEZ DIAZ
FRANCISCO VILCHEZ MARQUEZ
ANA DOLORES UBAGO RODRIGUEZ
CARLOS CUENCA BARRALES
RACHEL SANABRIA DE LA TORRE
AGUSTIN BUENDIA EISMAN
ANTONIO MARTINEZ LOPEZ
ALEJANDRO MOLINA LEYVA
ALVARO SIERRA SANCHEZ
JESUS TERCEDOR SANCHEZ
SALVADOR ARIAS SANTIAGO
GONZALO BLASCO MORENTE
MARIA SIERRA GIRON PRIETO
Prevalence and implications of type D personality in patients with alopecia areata: A marker of quality-of-life impairment and mood status disturbances, a comparative study
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023;
FI: 9,2; D1
Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study
DERMATOLOGY, 2023;
FI: 3,4; Q2
Medical students' interest in research: changing trends during university training
FRONTIERS IN MEDICINE, 2023;
FI: 3,9; Q2
Risk factors of quality-of-life and sexual function impairment in chronic spontaneous urticaria patients: cross-sectional study.
DERMATOLOGY, 2023;
FI: 3,4; Q2
ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis
BIOMEDICINE, 2023;
FI: 4,7; Q2
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
BRITISH JOURNAL OF DERMATOLOGY, 2022;
FI: 11,113; D1
Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia
FRONTIERS IN ENDOCRINOLOGY, 2022;
FI: 6,055; Q1
Potential Benefits of the Mediterranean Diet and Physical Activity in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study in a Spanish Population
NUTRIENTS, 2022;
FI: 6,706; Q1
The Contribution of Wnt Signaling to Vascular Complications in Type 2 Diabetes Mellitus
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response
JOURNAL OF CLINICAL MEDICINE, 2022;
FI: 4,964; Q2
Cellular human tissue-engineered skin substitutes investigated for deep and difficult to heal injuries
NPJ REGENERATIVE MEDICINE, 2021;
FI: 10,364; D1
Alloreactive Immune Response Associated with Human Mesenchymal Stromal Cells Treatment: A Systematic Review.
JOURNAL OF CLINICAL MEDICINE, 2021;
FI: 4,242; Q1
Biodistribution of Mesenchymal Stromal Cells after Administration in Animal Models and Humans: A Systematic Review.
JOURNAL OF CLINICAL MEDICINE, 2021;
FI: 4,242; Q1
Cumulative Inflammation and HbA1c Levels Correlate with Increased Intima-Media Thickness in Patients with Severe Hidradenitis Suppurativa
JOURNAL OF CLINICAL MEDICINE, 2021;
FI: 4,242; Q1
Capillary malformation-arteriovenous malformation syndrome: a multicentre study
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021;
FI: 3,47; Q2
Bioengineered Skin Intended as In Vitro Model for Pharmacosmetics, Skin Disease Study and Environmental Skin Impact Analysis
BIOMEDICINE, 2020;
FI: 4,717; Q1
Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020;
FI: 4,556; Q1
Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice
DERMATOLOGICAL THERAPY, 2020;
FI: 2,327; Q2
Could vascular endothelial growth factor inhibitors induce hidradenitis suppurativa? Report of three patients with renal cancer treated with sunitinib
DERMATOLOGICAL THERAPY, 2020;
FI: 2,327; Q2
A case report of severe dermatitis, allergies, and metabolic wasting (SAM syndrome)
PEDIATRIC DERMATOLOGY, 2020;
FI: 1,164; Q4
Sexual Distress in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study
JOURNAL OF CLINICAL MEDICINE, 2019;
FI: 5,688; D1
Association Between Psoriasis and Sexual and Erectile Dysfunction in “Epiderniologic Studies A Systenidtic Review
JAMA DERMATOLOGY, 2019;
FI: 7,995; D1
Use of topical rapamycin in the treatment of superficial lymphatic malformations
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019;
FI: 7,102; D1
Femoral artery ultrasound for improving the detection of atherosclerosis in psoriasis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019;
FI: 7,102; D1
Factors influencing frontal fibrosing alopecia severity: a multicenter cross-sectional study
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019;
FI: 5,113; D1
Genetic deregulation, immunological alteration and epidermal barrier dysfunction as biomarkers of therapeutic response in patients with atopic dermatitis
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI23 / 01875
Execution time: 01/01/2024 - 31/12/2026
PI: SALVADOR ARIAS SANTIAGO
Phase II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells from adipose tissue for the treatment of severe alopecia areata
Funder: COUNCIL OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE AND UNIVERSITIES
File number: PY20_01283
Execution time: 01/06/2021 - 31/12/2022
PI: ANTONIO MARTINEZ LOPEZ
Technological feasibility and valorization of artificial tissues based on fibrin-agarose
Funder: FOUNDATION FOR INNOVATION AND PROSPECTIVE IN HEALTH IN SPAIN
File number: 00-00002491-16
Execution time: 19/01/2017 - 19/07/2017
PI: SALVADOR ARIAS SANTIAGO
Clinical, Histological and Cutaneous Homeostasis Evaluation of an Autologous Human Artificial Skin Model Created by Tissue Engineering in Large Burned Patients.
Funder: COUNCIL OF HEALTH
File number: PI-0458-2016
Execution time: 01/01/2017 - 31/12/2019
PI: SALVADOR ARIAS SANTIAGO
Phase I-II clinical trial to evaluate the safety and efficacy of a tissue-engineered autologous skin model in basal cell carcinoma reconstructive surgery
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI17 / 02083
Execution time: 01/01/2018 - 31/12/2020
PI: SALVADOR ARIAS SANTIAGO
Randomized, double-blind, parallel, placebo-controlled phase II trial to determine the safety and efficacy of human allogeneic mesenchymal cells in the treatment of complex fistulas in patients with hidradenitis suppurativa
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PIGE-0247-2019
Execution time: 23/12/2019 - 22/12/2022
IP: ALEJANDRO MOLINA LEYVA
PRECLINICAL EVALUATION UNDER GMP CONDITIONS OF A NEW MODEL OF ARTIFICIAL HUMAN SKIN CARRIED OUT WITH ALLOGENIC TRUNK MESENCHYMAL CELLS OF ADIPOSE TISSUE INCORPORATED TO THE CONSTRUCTION OR INJECTED PERILESSIONALLY
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PIGE-0242-2019
Execution time: 23/12/2019 - 22/12/2022
PI: ANTONIO MARTINEZ LOPEZ
Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of upadacitinib in adult and adolescent subjects with moderate or severe hidradenitis suppurativa who have not responded to anti-TNF therapy
Funder: ABBVIE SPAIN SLU
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 13/06/2023 - 30/01/2026
IP: ALEJANDRO MOLINA LEYVA
Real-life evidence of certolizumab pegol treatment in adult patients with moderate to severe psoriasis. Arcoderm study.
Financier: ANDRES NAVARRO RUIS / FERNANDO TOLEDO ALBEROLA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 01/02/2023 - 30/10/2023
PI: SALVADOR ARIAS SANTIAGO
Multicenter, prospective, observational study to measure the benefits of tildrakizumab in achieving therapeutic goals in patients with moderate or severe plaque psoriasis and inadequate response to treatments with biological drugs
Financier: ALMIRALL SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 03/10/2023 - 30/06/2026
PI: ANTONIO MARTINEZ LOPEZ
Phase I/IIa, Randomized, Placebo-Controlled, Single-Rising-Dose (Part A, Participant- and Investigator-Blinded) and Repeated-Dose (Part B, Participant-, Investigator- and Sponsor-Blinded) Study
Funder: UCB PHARMA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 06/06/2023 - 30/12/2023
IP: TRINIDAD MONTERO VILCHEZ
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Financer: INCYTE CORPORATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 17/02/2023 - 28/02/2026
IP: ALEJANDRO MOLINA LEYVA
Phase III, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the efficacy and safety of tirbanibulin 10 mg/g ointment applied to a treatment field greater than 25 cm² and up to
Financier: ALMIRALL SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 01/12/2023 - 30/04/2025
IP: FRANCISCO VILCHEZ MARQUEZ
A 24-month prospective, observational cohort study to evaluate oral systemic therapies in the treatment of adult patients with atopic dermatitis in real life (AD-REAL)
Funder: ELI LILLY AND COMPANY
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 13/04/2023 - 30/12/2025
IP: TRINIDAD MONTERO VILCHEZ
Retrospective observational study to describe the evaluation of the disease in patients with stage II cutaneous melanoma in Spain. METHEOR Studio
Financier: BRISTOL-MYERS SQUIBB, SAU
Test type: REST OF EEOO WITH MEDICATIONS
Execution time: 27/05/2022 - 30/01/2023
IP: FRANCISCO VILCHEZ MARQUEZ
TRACE. Real-life clinical use of tralokinumab Observational cohort study of patients with atopic dermatitis prescribed tralokinumab.
Funder: LEO PHARMA A / S
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 18/10/2022 - 30/12/2024
PI: SALVADOR ARIAS SANTIAGO
Real-Life Use of Upadacitinib in Adult and Adolescent Patients Suffering from Moderate to Severe Atopic Dermatitis (AD-VISE)
Funder: ABBVIE SPAIN SLU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 12/07/2022 - 30/12/2025
IP: TRINIDAD MONTERO VILCHEZ
Observational, prospective and multicenter study to determine the degree of well-being perceived by patients treated with tildrakizumab under conditions of routine clinical practice: POSITIVE study
Financier: ALMIRALL SA
Test type: OBS STUDY. WITH MED. SECURITY PROSPECT.
Execution time: 08/07/2022 - 08/05/2025
PI: SALVADOR ARIAS SANTIAGO
Phase 3b/4 randomized, open-label, evaluator-blind study to compare the safety and evaluator-blind efficacy of upadacitinib versus dupilumab in patients with moderate or severe atopic dermatitis (Level-Up).
Funder: ABBVIE DEUTSCHLAND GMBH & CON K. G
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 01/12/2022 - 30/10/2026
IP: TRINIDAD MONTERO VILCHEZ
Open-label phase IV study to evaluate the impact of tirbanibulin on the well-being of patients with actinic keratosis (TIRBASKIN).
Financier: ALMIRALL SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 14/11/2022 - 30/10/2023
IP: FRANCISCO VILCHEZ MARQUEZ
Phase IV, multicenter, randomized, evaluator-blind, comparative study with active treatment to determine the incidence of squamous cell carcinoma and evaluate the long-term safety of the administration of tirbanibulin 10 mg/g ointment and diclofenac sodium 3% gel for the treatment of adult patients with actinic keratosis on the face or scalp.
Financier: ALMIRALL SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 15/07/2022 - 30/06/2026
IP: FRANCISCO VILCHEZ MARQUEZ
Phase I-II Clinical Trial, Single-center, Randomized, Double-Blind, placebo-controlled, to determine the safety and efficacy of the use of allogeneic adult mesenchymal stem cells from adipose tissue, in the treatment of draining fistulas of patients with hidradenitis suppurativa.
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/09/2022 - 30/01/2026
IP: ALEJANDRO MOLINA LEYVA
Multicenter, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of lutikizumab (ABT-981) in adult subjects with moderate or severe hidradenitis suppurativa who have not responded to anti-TNF treatment.
Funder: ABBVIE SPAIN SLU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 07/02/2022 - 30/04/2024
IP: ALEJANDRO MOLINA LEYVA
Phase 3, open-label, parallel-group, multicenter extension study of a previous study, to evaluate long-term treatment with bimekizumab in subjects with moderate or severe hidradenitis suppurativa
Funder: UCB PHARMA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 27/12/2021 - 06/04/2025
IP: ALEJANDRO MOLINA LEYVA
Platform, randomized, double-blind (patient and investigator), placebo-controlled, multicenter study to evaluate the efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa.
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 06/04/2022 - 30/07/2023
IP: ALEJANDRO MOLINA LEYVA
Phase II, randomized, double-blind, placebo-comparative, dose-finding study to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis.
Financer: INCYTE CORPORATION
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 20/06/2022 - 30/07/2023
IP: TRINIDAD MONTERO VILCHEZ
Multinational, observational cohort study of patients with moderate to severe chronic plaque psoriasis. VALUE study / P19-377
Funder: ABBVIE SPAIN SLU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 31/05/2021 - 30/06/2025
PI: ANTONIO MARTINEZ LOPEZ
Characterization of the Adult Patient with Moderate to Severe Atopic Dermatitis (AD) in Dermatology Units of the hospital setting in Spain. DACAR STUDIO
Financer: LABORATORIOS LEO PHARMA, SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 22/04/2021 - 31/07/2021
IP: JESUS TERCEDOR SANCHEZ
Randomized, double-blind, multicenter phase III trial to evaluate the efficacy and tolerability of brodalumab compared with the use of placebo (blind) and ustekinumab (open) in adolescent patients (12-17 years of age) with psoriasis in pl
Funder: LEO PHARMA A / S
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 03/02/2021 - 30/12/2024
PI: ANTONIO MARTINEZ LOPEZ
Phase II, randomized, double-blind, placebo-controlled, cross-dose-range study to evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa
Financer: INCYTE CORPORATION
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 19/02/2021 - 30/09/2022
IP: ALEJANDRO MOLINA LEYVA
Adjustable dosing regimens of brodalumab compared to standard brodallumab treatment for 52 weeks in patients with moderate to gravel plaque psoriasis and> = 120 kg of body weight. ADJUST STUDY
Funder: LEO PHARMA A / S
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 31/08/2020 - 30/09/2025
PI: ANTONIO MARTINEZ LOPEZ
An international, multicenter, open-label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100mg in patients with moderate to severe chronic plaque psoriasis and its influence on quality of life
Financier: ALMIRALL SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 14/02/2020 - 30/09/2021
PI: ANTONIO MARTINEZ LOPEZ
Phase ii clinical trial to evaluate the safety and efficacy of two tissue-engineered autologous skin models in basal cell carcinoma reconstructive surgery
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 03/09/2020 - 31/03/2021
PI: SALVADOR ARIAS SANTIAGO
Randomized, double-blind, multicenter withdrawal extension study to demonstrate the long-term efficacy, safety, and tolerability of subcutaneous secukinumab in patients with moderate to severe hidradenitis suppurativa
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 10/01/2020 - 18/06/2025
IP: ALEJANDRO MOLINA LEYVA
A phase 3, andomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa
Funder: UCB BIOSCIENCES GMBH
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/08/2020 - 30/04/2023
IP: ALEJANDRO MOLINA LEYVA
Single-arm, open-label, multicenter, long-term extension trial to evaluate the safety and efficacy of tralokinumab in patients with atopic dermatitis who participated predominantly in clinical trials with tralokinumab: ECZTEND.
Funder: LEO PHARMA A / S
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 27/04/2020 - 30/10/2021
IP: JESUS TERCEDOR SANCHEZ
Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of risankizumab in adults with moderate or severe hidradenitis suppurativa.
Funder: ABBVIE SPAIN SLU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 13/11/2019 - 30/06/2022
IP: ALEJANDRO MOLINA LEYVA
